Fig 1.
AFP, serum alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; HCC, hepatocellular carcinoma; US, abdominal ultrasonography.
Table 1.
Characteristics of 1,289 enrolled patients with Barcelona Clinic Liver Cancer stage 0-A single-nodular hepatocellular carcinoma detected during US surveillance.
Table 2.
Distribution of hepatocellular carcinoma tumors by characteristic and blind spot location on ultrasonography.
Fig 2.
Comparison of the size distribution of HCC by blind vs. non-blind spot location.
HCC, hepatocellular carcinoma.
Fig 3.
Comparison of the size distribution of HCC in blind spots of the total study population.
HCC, hepatocellular carcinoma; US, ultrasonography; *Definition of blind spots: hepatic dome (blind spot 1), caudate lobe or around the inferior vena cava (blind spot 2), <1 cm beneath the ribs (blind spot 3), and surface of the left lateral segment (blind spot 4).
Table 3.
Baseline parameters related to detection of hepatocellular carcinoma tumors located within blind spots during surveillance.
Table 4.
Differences in initial treatment by HCC tumor size and location.
Fig 4.
Overall survival of the US-detected versus US-missed groups: (A) entire study population, (B) HCC in a blind spot, and (C) HCC in a non-blind area (P value calculated by the log-rank test).
Table 5.
Factors associated with overall survival in patients with single-nodular HCC detected during US surveillance.